Table 2 Summary of ongoing clinical trials using new generation of CAR T cells in solid tumors
Intervention | Phase | Treated cancers | Primary outcome measures | Clinical Trials Identifier | Status |
|---|---|---|---|---|---|
CTLA-4/PD-1 antibody expressing mesothelin-CAR T cells | I/II | Advanced solid tumor | Number of adverse events | NCT03182803 | Recruiting |
PD-1 antibody expressing mesothelin-specific CAR T cells | I/II | Advanced solid tumor | Safety profile of treatments | NCT03030001 | Recruiting |
CTLA-4/PD-1 antibody expressing MUC-1 CAR T cells | I/II | Advanced solid tumor | Safety and toxicity profile of treatments | NCT03179007 | Recruiting |